Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155693723> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2155693723 endingPage "424" @default.
- W2155693723 startingPage "419" @default.
- W2155693723 abstract "Between January 1976 and June 1981, 814 patients with pulmonary tuberculosis were treated for 9 months with isoniazid (INH) and rifampin (RIF), daily for 1 month and twice weekly for the other 8 months. Overall success was achieved in 95% of the 586 patients who completed therapy: in 15 patients (2.9%), sputum cultures failed to convert to negative during therapy, and 10 patients (1.7%) have relapsed since stopping the chemotherapy. Major toxic effects occurred in 22 patients; in 14 during the daily phase and in 8 during the twice-weekly phase. Hepatic toxicity occurred in 13 patients during daily and in 5 during twice-weekly treatment, and it was caused by RIF in 5, INH in 10, and was undetermined in 3. Hematologic abnormalities developed in 4 patients: in 1 during the daily and in 3 during the twice-weekly phase. Minor side effects, which were not life threatening, were encountered in 62 patients: in 35 during the daily and in 27 during the twice-weekly therapy. These were gastrointestinal intolerance in 18, drug fever in 27 (including 11 with flu-syndrome during twice-weekly administration), cutaneous rashes in 14, and headache, general malaise, and weakness in 3. These side effects were produced by RIF in 43, by INH in 18, and the responsible drug was not identified in 1. Hypersensitivity reactions to twice-weekly administration of RIF were infrequent. Clinical surveillance for toxicity is preferred over routine and regular biochemical monitoring." @default.
- W2155693723 created "2016-06-24" @default.
- W2155693723 creator A5006537696 @default.
- W2155693723 creator A5049232373 @default.
- W2155693723 creator A5066984537 @default.
- W2155693723 date "1983-09-01" @default.
- W2155693723 modified "2023-10-03" @default.
- W2155693723 title "Undesirable Side Effects of Isoniazid and Rifampin in Largely Twice-Weekly Short-Course Chemotherapy for Tuberculosis" @default.
- W2155693723 cites W1973717819 @default.
- W2155693723 cites W1974015314 @default.
- W2155693723 cites W1979992991 @default.
- W2155693723 cites W1986812116 @default.
- W2155693723 cites W1987383540 @default.
- W2155693723 cites W2016083420 @default.
- W2155693723 cites W2030269053 @default.
- W2155693723 cites W2050183622 @default.
- W2155693723 cites W2060886162 @default.
- W2155693723 cites W2114935282 @default.
- W2155693723 doi "https://doi.org/10.1164/arrd.1983.128.3.419" @default.
- W2155693723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6614636" @default.
- W2155693723 hasPublicationYear "1983" @default.
- W2155693723 type Work @default.
- W2155693723 sameAs 2155693723 @default.
- W2155693723 citedByCount "50" @default.
- W2155693723 countsByYear W21556937232012 @default.
- W2155693723 countsByYear W21556937232015 @default.
- W2155693723 countsByYear W21556937232016 @default.
- W2155693723 countsByYear W21556937232017 @default.
- W2155693723 countsByYear W21556937232019 @default.
- W2155693723 countsByYear W21556937232021 @default.
- W2155693723 countsByYear W21556937232022 @default.
- W2155693723 crossrefType "journal-article" @default.
- W2155693723 hasAuthorship W2155693723A5006537696 @default.
- W2155693723 hasAuthorship W2155693723A5049232373 @default.
- W2155693723 hasAuthorship W2155693723A5066984537 @default.
- W2155693723 hasConcept C126322002 @default.
- W2155693723 hasConcept C141071460 @default.
- W2155693723 hasConcept C142724271 @default.
- W2155693723 hasConcept C2776301714 @default.
- W2155693723 hasConcept C2776694085 @default.
- W2155693723 hasConcept C2776967927 @default.
- W2155693723 hasConcept C2779277585 @default.
- W2155693723 hasConcept C2781069245 @default.
- W2155693723 hasConcept C29730261 @default.
- W2155693723 hasConcept C71924100 @default.
- W2155693723 hasConcept C90924648 @default.
- W2155693723 hasConceptScore W2155693723C126322002 @default.
- W2155693723 hasConceptScore W2155693723C141071460 @default.
- W2155693723 hasConceptScore W2155693723C142724271 @default.
- W2155693723 hasConceptScore W2155693723C2776301714 @default.
- W2155693723 hasConceptScore W2155693723C2776694085 @default.
- W2155693723 hasConceptScore W2155693723C2776967927 @default.
- W2155693723 hasConceptScore W2155693723C2779277585 @default.
- W2155693723 hasConceptScore W2155693723C2781069245 @default.
- W2155693723 hasConceptScore W2155693723C29730261 @default.
- W2155693723 hasConceptScore W2155693723C71924100 @default.
- W2155693723 hasConceptScore W2155693723C90924648 @default.
- W2155693723 hasIssue "3" @default.
- W2155693723 hasLocation W21556937231 @default.
- W2155693723 hasLocation W21556937232 @default.
- W2155693723 hasOpenAccess W2155693723 @default.
- W2155693723 hasPrimaryLocation W21556937231 @default.
- W2155693723 hasRelatedWork W1698118555 @default.
- W2155693723 hasRelatedWork W2055131868 @default.
- W2155693723 hasRelatedWork W2143106056 @default.
- W2155693723 hasRelatedWork W2284278433 @default.
- W2155693723 hasRelatedWork W2397336125 @default.
- W2155693723 hasRelatedWork W2412055222 @default.
- W2155693723 hasRelatedWork W2418173552 @default.
- W2155693723 hasRelatedWork W2619764267 @default.
- W2155693723 hasRelatedWork W3165151283 @default.
- W2155693723 hasRelatedWork W4284883503 @default.
- W2155693723 hasVolume "128" @default.
- W2155693723 isParatext "false" @default.
- W2155693723 isRetracted "false" @default.
- W2155693723 magId "2155693723" @default.
- W2155693723 workType "article" @default.